Flexible pricing in action
Following the update of national treatment guidelines in Brazil to recommend DTG as the preferred first-line therapy for treatment-naïve patients as well as third-line therapy for treatment-experienced patients and in post-exposure prophylaxis - we worked with the Brazilian MoH to enable broader access to DTG to those in greatest need in the country.
In line with of our global access strategy and commitment to accelerate access to antiretrovirals for PLHIV, we established a high volume low cost price arrangement with the Brazilian MoH enabled by our flexible pricing policy for middle income countries. This factored in MoH budget constraints, the specific gross national income and the impact of the epidemic in the country to improve affordability and enable all new patients to be initiated on DTG. Late line patients on more expensive products could also be switched to DTG, thereby maintaining overall cost neutrality for the MOH and increasing access to patients.
Under the tender agreement, we provided the MoH with approximately 1.3 million packs of DTG 50 mg tablets in 2017, which were prescribed to approximately 100,000 PLHIV in Brazil.